Pfizer, Inc. — PFE
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $25.58 | $145.44B | 14.9 | 8.6 | 8.2% | 2.6% | $1.72 6.7% | 1.6 |
Latest Headlines
- · JPM26: BioNTech gears up for multiproduct oncology status by 2030
- · PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock
- · BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan
- · [Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
- · Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025
- · JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $41.7B | $9.2B | $1.73 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $81.3B | $22.0B | $3.92 | 95.2% | 140.0% | 126.6% |
| 2 | 2022-12-31 | $100.3B | $31.4B | $5.59 | 23.4% | 42.7% | 42.6% |
| 3 | 2023-12-31 | $58.5B | $2.1B | $0.38 | -41.7% | -93.2% | -93.2% |
| 4 | 2024-12-31 | $63.6B | $8.0B | $0.38 | 8.8% | 279.0% | 0.0% |
| 5 | TTM 2025-03-31 | $62.5B | $7.9B | $1.38 | -1.8% | -1.8% | 263.2% |
| 6 | Average | 16.8% | 73.3% | 67.8% |
EPS
Forecasts
Y/Y % Change
PFE Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 95.2% | 23.4% | -41.7% | 8.8% | -2.6% | -2.4% | 13.4% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 4 | 4 | |
| EPS Growth (%) | 140.0% | 42.7% | -93.2% | 279.0% | 121.6% | -3.5% | 81.1% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|
| 2021 | $81.3B | $24.1B | $13.8B | $12.7B | $5.2B |
| 2022 | $101.2B | $27.8B | $12.4B | $13.7B | $5.1B |
| 2023 | $59.6B | $17.1B | $10.9B | $14.8B | $6.3B |
| 2024 | $63.6B | $9.1B | $10.9B | $14.7B | $7.0B |
| TTM | $62.8B | $8.3B | $11.8B | $13.9B | $6.7B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|
| 2022 | 24.46 | 15.27 | -10.47 | 7.67 | -2.45 |
| 2023 | -41.14 | -38.52 | -12.18 | 8.00 | 24.21 |
| 2024 | 6.84 | -46.74 | 0.52 | -0.28 | 11.49 |
| TTM | -1.32 | -8.73 | 7.55 | -5.59 | -4.52 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $206,095M |
| 1 | Cash | $1,638M |
| 2 | Total Liabilities | $117,083M |
| 3 | Total Debt | $60,926M |
| 4 | Total Equity | $88,695M |
| 5 | Debt to Equity Ratio | 0.69 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $25.58 | 4.1% | Nicks Growth: 2% Nick's Expected Margin: 10% FINVIZ Growth: -3% |
Nicks: 8 Finviz: 5 |
Nick's: 0.805 | 2.3 | 14.9 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $1.72 EPS | TTM | $13.85 | -45.8% | $8.61 | -66.4% |
| $3.13 EPS | 2025 | $25.21 | -1.4% | $15.66 | -38.8% |
| $3.02 EPS | 2026 | $24.33 | -4.9% | $15.11 | -40.9% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 8.00% | 2.54% | 7.87% | 2.51% | 1.41% | 0.30% | 8.04% | 2.48% | 62.0% | 47.3% |
| 3 Years | 8.00% | 2.54% | 7.87% | 2.51% | 1.41% | 0.30% | 8.04% | 2.48% | 62.0% | 47.3% |
| 5 Years | 8.00% | 2.54% | 7.87% | 2.51% | 1.41% | 0.30% | 8.04% | 2.48% | 62.0% | 47.3% |
| 10 Years | 8.00% | 2.54% | 7.87% | 2.51% | 1.41% | 0.30% | 8.04% | 2.48% | 62.0% | 47.3% |